Okyanos Heart Institute

What Okyanos Heart Institute does

Okyanos Heart Institute is a privately held, for-profit cardiac regenerative-medicine clinic founded in 2011 and headquartered in Freeport, Bahamas. Per its own short description, the clinic is positioned to deliver a "new standard of care and a better quality of life" through an EU-approved cell therapy applied to cardiac conditions, suggesting a stem-cell-based treatment offering for heart disease patients. Its Bahamas domicile is consistent with a medical-tourism model serving international (likely U.S.) patients seeking cell therapies outside their domestic regulatory environment.

The clinic operates at small scale, with an employee base in the 11–50 range and a leadership team that includes a Chief Medical Officer (Howard T. Walpole) and a Senior Vice President (Erika Rosenthal). The company completed a single disclosed funding round in March 2014, raising approximately $8.9 million from undisclosed investors. No product pipeline beyond the cell-therapy service offering, no partnerships, no certifications, no customer logos, and no pricing details are documented in available sources. The company's public website currently displays only a verification/loading screen, limiting independent verification of operational status, treatment protocols, or patient outcomes.

Commercially, the clinic appears to monetize per-patient treatment fees typical of elective, high-ticket regenerative-medicine procedures; however, no pricing model, patient volume, or revenue figures are disclosed. Ownership structure, investor composition, and current operating status cannot be reliably determined from available data.

Name

Okyanos Heart Institute

Website

https://okyanos.com

Company type

Private

Founded year

2011

Headcount range

11–50 employees

Short description

Okyanos Heart Institute is a private cardiac regenerative-medicine clinic in Freeport, Bahamas, founded in 2011, that delivers EU-approved cell therapy to heart-disease patients, primarily through a medical-tourism model serving international clientele.

Ownership category

akta.pro rank

Product category

Regenerative Cardiology

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

General Cardiology (Consultative) (HLAKABAA)

akta.pro secondary industry

Heart Failure & Transplant Cardiology (HLAKABAD)

Keywords

• Cardiac cell therapy
• Regenerative medicine
• Heart disease treatment
• Stem cell therapy
• Cardiovascular care

Headquarters

HQ city

Freeport

HQ country

Bahamas

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Core offering

Okyanos Heart Institute is a regenerative medicine clinic that delivers cell-based therapies to patients with cardiovascular conditions. Founded in 2011 and headquartered in Freeport, Bahamas, the institute provides treatments that use European Union-approved cells to bring a new standard of care and improved quality of life to patients with chronic heart disease and related cardiac conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiac Cell Therapy

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Emerging players

• Capricor Therapeutics: Clinical-stage biotech developing cell-derived therapeutics for cardiac diseases including heart failure. Comparable as a cardiac cell-therapy development counterparty and as a potential upstream/differentiation reference.
• Mesoblast: Late-stage cell-therapy company with cardiovascular programs including chronic heart failure. Comparable as a broader cardiac regenerative-medicine peer shaping the field's clinical and reimbursement trajectory.
• BioCardia: Cell therapy company with cardiac-delivery platform targeting heart failure. Comparable in its cardiac-cell-therapy focus; relevant as a peer in the cardiac regenerative-medicine ecosystem.

Broad incumbents

• Cleveland Clinic Heart, Vascular & Thoracic Institute: Nationally ranked cardiac program within a major academic medical center. Comparable as an enterprise-scale destination for complex cardiac care; broader portfolio but overlapping patient population.
• Mayo Clinic Cardiovascular Medicine: Comprehensive cardiovascular medicine practice within a top-ranked academic medical center. Comparable as a destination cardiac provider; broader scale and service mix than Okyanos.
• Cedars-Sinai Heart Institute: Large hospital-affiliated heart institute offering comprehensive cardiac care, including interventional and surgical services. Comparable as a high-acuity cardiac destination, though embedded within a broader health system.

Direct peers

• StemGenex Stem Cell Therapy Centers: Autologous adult stem cell therapy provider focused on regenerative treatments across multiple conditions including cardiac. Directly comparable as an early commercial cell-therapy clinic.
• Regeneris Medical: Regenerative medicine clinic offering stem cell and PRP therapies, including for cardiac indications. Comparable to Okyanos in clinical cell-therapy delivery model and patient-acquisition approach.
• Texas Heart Institute: Independent specialty cardiac institute focused on heart disease treatment, research, and education. Directly comparable to Okyanos as a destination cardiac-care provider serving patients with advanced heart conditions.
• Minneapolis Heart Institute: Independent specialty cardiac care provider delivering full-spectrum cardiovascular services. Comparable to Okyanos as a focused, destination-oriented cardiac practice.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/OkyanosHeart
• Facebookfacebook.com/OKYANOS
• LinkedInlinkedin.com/company/okyanos-heart-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okyanos Heart Institute